Skip to main content

Genomic Health Uses Tecan Workstations to Automate Cancer Assay Development

NEW YORK (GenomeWeb News) - Genomic Health is using Tecan’s liquid-handling workstations to automate the developmental process for its cancer recurrence assays, Tecan said this week.
 
Genomic Health markets Oncotype DX, a gene expression assay that predicts the risk of recurrence of cancer and the likelihood of chemotherapy benefit in early-stage breast cancer patients.
 
Genomic Health’s director of process automation, Jay Snable, said the company is using the Tecan technology as part of a new project that is studying 761 genes “in an initial screen to create a gene profile for an assay to test for risk of recurrence of another cancer type.”
 
The company is using Tecan’s Freedom EVO 200 and Genesis platforms to automate all assay steps after RNA extraction, including RNA quantification and quality control, reverse transcription, and quantitative PCR assay assembly.
 
The workstations are also equipped with Tecan’s PosID barcode-scanning system, Tecan said.
 
Financial terms of the agreement were not released.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.